Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00246493 |
Recruitment Status
:
Terminated
First Posted
: October 31, 2005
Last Update Posted
: April 24, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The prevalence, incidence, and severity of atherosclerotic disease all markedly increase with age. Basic experimental and observational data demonstrate that aging magnifies the pathologic and clinical consequences of established risk factors and is the most potent individual risk factor for coronary atherosclerosis and for adverse outcomes following an ischemic event. These findings suggest that normal aging alters the vascular substrate so as to promote the development and progression of atherosclerosis. The age-associated changes in vascular structure and function include an increase in central vascular stiffness, intimal proliferation, and endothelial dysfunction. The major hypothesis is that the above alterations in vascular substrate (i.e. vascular age) are an important determinant of the age associated increased likelihood for the development and progression of coronary atherosclerotic disease.
This program will non-invasively characterize vascular age and atherosclerotic burden in BLSA participants and individuals with successful aging, i.e. those with no or minimal evidence of coronary atherosclerotic disease, and those with premature, clinically evident coronary artery disease. It will repeat measures of vascular age and atherosclerotic burden three years after the first assessment. By examining the impact of vascular age on the initial extent and the progression of atherosclerotic burden over a two to three-year period, it will test the hypothesis that vascular age is an important determinant of the ageassociated increase in atherosclerotic disease.
Condition or disease |
---|
Atherosclerosis Cardiovascular Disease Vascular Diseases |
The prevalence, incidence, and severity of atherosclerotic disease all markedly increase with age. Basic experimental and observational data demonstrate that aging magnifies the pathologic and clinical consequences of established risk factors and is the most potent individual risk factor for coronary atherosclerosis and for adverse outcomes following an ischemic event. These findings suggest that normal aging alters the vascular substrate so as to promote the development and progression of atherosclerosis. The age-associated changes in vascular structure and function include an increase in central vascular stiffness, intimal proliferation, and endothelial dysfunction. The major hypothesis is that the above alterations in vascular substrate (i.e. vascular age) are an important determinant of the age associated increased likelihood for the development and progression of coronary atherosclerotic disease.
This protocol will non-invasively characterize vascular age and atherosclerotic burden in BLSA participants and individuals with successful aging, i.e. those with no or minimal evidence of coronary atherosclerotic disease, and those with premature, clinically evident coronary artery disease. It will repeat measures of vascular age and atherosclerotic burden three years after the first assessment. By examining the impact of vascular age on the initial extent and the progression of atherosclerotic burden over a two to three-year period, it will test the hypothesis that vascular age is an important determinant of the age-associated increase in atherosclerotic disease.
Study Type : | Observational |
Actual Enrollment : | 495 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study) |
Study Start Date : | June 22, 2004 |
Study Completion Date : | November 1, 2017 |

- Characterize vascular age relat-BLSA [ Time Frame: Two-three years ]
- Characterize vascular age relat-other [ Time Frame: Two-three years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
- INCLUSION CRITERIA:
For all groups:
- Age 30 years or older
- Ability and willingness to participate in the protocol and undergo vascular studies and chest MDCT examinations
For the second group:
1) Coronary artery calcium score of zero or less than 25th percentile of that expected based on age and gender.
For the third group:
1) Coronary artery calcium score which is greater than the 50th percentile of that computed based on age and gender, or known coronary disease on the basis of:
i. prior documented myocardial infarction or
ii. typical ischemic symptoms and catheterization documented stenosis of greater than or equal to 70% in at least one major coronary artery
If male, diagnosis was made under 50 years of age
If female, diagnosis was made under 60 years of age.
EXCLUSION CRITERIA
- Atrial fibrillation (due to limitations with gating on MDCT)
- For the first 2 groups: History of procedures used for treatment of CVD (CABG, angioplasty, pacemaker or defibrillator implantation, any surgery on the heart or the arteries)
- Active treatment for cancer
- Serious medical condition which could hinder participation or make it unlikely that they will live for three years (for f/u)
- Weight>300 lb (maximum weight allowed on CT tables)
- Inability to provide an informed consent
- For females, current pregnancy because of the radiation associated with the helical CT and the unknown risks to a fetus. This is only temporary, and women wishing to participate may be enrolled six weeks after delivery.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00246493
United States, Maryland | |
Johns Hopkins University | |
Baltimore, Maryland, United States, 21205 | |
National Institute of Aging, Clinical Research Unit | |
Baltimore, Maryland, United States, 21224 |
Principal Investigator: | Edward G Lakatta, M.D. | National Institute on Aging (NIA) |
Publications:
Responsible Party: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00246493 History of Changes |
Other Study ID Numbers: |
999904294 04-AG-N294 |
First Posted: | October 31, 2005 Key Record Dates |
Last Update Posted: | April 24, 2018 |
Last Verified: | November 1, 2017 |
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute on Aging (NIA) ):
Coronary Endothelial Vascular Atherosclerosis Arterial |
Additional relevant MeSH terms:
Cardiovascular Diseases Atherosclerosis Vascular Diseases Arteriosclerosis Arterial Occlusive Diseases |